(Q37239001)

19 August 2017

1 reference

title

The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias (English)

1 reference

19 August 2017

0 references

0 references

5

Colin L Masters

1 reference

19 August 2017

Victor L Villemagne

1

1 reference

19 August 2017

Michelle T Fodero-Tavoletti

2

1 reference

19 August 2017

Kerryn E Pike

3

1 reference

19 August 2017

Roberto Cappai

4

1 reference

19 August 2017

Christopher C Rowe

6

1 reference

19 August 2017

9 August 2008

1 reference

19 August 2017

Molecular Neurobiology

1 reference

19 August 2017

38

1 reference

19 August 2017

1

1 reference

19 August 2017

1-15

1 reference

https://scigraph.springernature.com/pub.10.1007/s12035-008-8019-y

19 August 2017

0 references

cites work

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

The course of psychopathologic features in mild to moderate Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

Memory decline in healthy older people: implications for identifying mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-008-8019-Y

Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease.

21 January 2018

1 reference

12 December 2020

Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography

1 reference

12 December 2020

Nicotine receptors in the brain of patients with Alzheimer's disease. Studies with 11C-nicotine and positron emission tomography

1 reference

12 December 2020

Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.

1 reference

12 December 2020

Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques.

1 reference

12 December 2020

Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development

1 reference

12 December 2020

123Iodo-MK-801: a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease.

1 reference

12 December 2020

Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils.

1 reference

12 December 2020

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

1 reference

12 December 2020

In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

1 reference

12 December 2020

On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer's disease

1 reference

12 December 2020

Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis

1 reference

12 December 2020

2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients.

1 reference

12 December 2020

Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease

1 reference

12 December 2020

Abeta amyloid deposition in the language system and how the brain responds

1 reference

12 December 2020

Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease

1 reference

12 December 2020

Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging

1 reference

12 December 2020

Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents

1 reference

12 December 2020

F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain

1 reference

12 December 2020

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

1 reference

12 December 2020

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease

1 reference

12 December 2020

PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.

1 reference

12 December 2020

Amyloid Abeta levels in Alzheimer's disease - A diagnostic tool and the key to understanding the natural history of Abeta?

1 reference

12 December 2020

Labeling of cerebral amyloid in vivo with a monoclonal antibody.

1 reference

12 December 2020

Causative and susceptibility genes for Alzheimer's disease: a review.

1 reference

12 December 2020

Alzheimer's disease: the amyloid cascade hypothesis

1 reference

12 December 2020

Magnetic resonance imaging of amyloid plaques in transgenic mice

1 reference

12 December 2020

Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study.

1 reference

12 December 2020

Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease

1 reference

12 December 2020

11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease

1 reference

12 December 2020

Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory

1 reference

12 December 2020

In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.

1 reference

12 December 2020

Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease

1 reference

12 December 2020

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

1 reference

12 December 2020

Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques

1 reference

12 December 2020

Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients

1 reference

12 December 2020

PET of brain amyloid and tau in mild cognitive impairment.

1 reference

12 December 2020

MRI of entorhinal cortex in mild Alzheimer's disease.

1 reference

12 December 2020

Opiate receptor avidity and cerebral blood flow in Alzheimer's disease.

1 reference

12 December 2020

Mild cognitive impairment: transition between aging and Alzheimer's disease.

1 reference

12 December 2020

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

1 reference

12 December 2020

The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention.

1 reference

12 December 2020

Clinical studies in Alzheimer patients with positron emission tomography

1 reference

12 December 2020

[18] Quantification of β-sheet amyloid fibril structures with thioflavin T

1 reference

12 December 2020

Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils.

1 reference

12 December 2020

The search for an amyloid solution.

1 reference

12 December 2020

Imaging of muscarinic receptors in the central nervous system

1 reference

12 December 2020

Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.

1 reference

12 December 2020

In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques

1 reference

12 December 2020

Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.

1 reference

12 December 2020

The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component.

1 reference

12 December 2020

[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

1 reference

12 December 2020

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics

1 reference

12 December 2020

Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.

1 reference

12 December 2020

Serotonin 1A receptors in the living brain of Alzheimer's disease patients

1 reference

12 December 2020

Positron emission tomography diagnosis of Alzheimer's disease

1 reference

12 December 2020

Neuropathology of Alzheimer's disease: a critical update.

1 reference

12 December 2020

MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease.

1 reference

12 December 2020

Amyloid plaque core protein in Alzheimer disease and Down syndrome

1 reference

12 December 2020

Imaging beta-amyloid burden in aging and dementia.

1 reference

12 December 2020

Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

1 reference

12 December 2020

The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging.

1 reference

12 December 2020

Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease

1 reference

12 December 2020

Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B.

1 reference

12 December 2020

Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies

1 reference

12 December 2020

Alzheimer's disease is a synaptic failure

1 reference

12 December 2020

Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.

1 reference

12 December 2020

Development and evaluation of iodinated tracers targeting amyloid plaques for SPECT imaging

1 reference

12 December 2020

Mild cognitive impairment: clinical characterization and outcome

1 reference

12 December 2020

11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.

1 reference

12 December 2020

19F and 1H MRI detection of amyloid beta plaques in vivo

1 reference

12 December 2020

Neuroimaging and early diagnosis of Alzheimer disease: a look to the future

1 reference

12 December 2020

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

1 reference

12 December 2020

Differential diagnosis of Alzheimer's disease with PET.

1 reference

12 December 2020

Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease

1 reference

12 December 2020

Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease

1 reference

12 December 2020

Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals.

1 reference

12 December 2020

Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease

1 reference

12 December 2020

Congo red and thioflavin-T analogs detect Abeta oligomers

1 reference

12 December 2020

Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease.

1 reference

12 December 2020

PET imaging of amyloid deposition in patients with mild cognitive impairment.

1 reference

12 December 2020

Early Intervention Is Key to Successful Management of Alzheimer Disease

1 reference

12 December 2020

Amyloid inhibitors and Alzheimer's disease

1 reference

12 December 2020

Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice

1 reference

12 December 2020

In vivo amyloid imaging with PET in frontotemporal dementia.

1 reference

12 December 2020

Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities.

1 reference

12 December 2020

In vivo amyloid imaging in Alzheimer's disease

1 reference

12 December 2020

PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.

1 reference

12 December 2020

A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain

1 reference

12 December 2020

Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo

1 reference

12 December 2020

Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography

1 reference

12 December 2020

In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile

1 reference

12 December 2020

Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease.

1 reference

12 December 2020

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

1 reference

12 December 2020

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

1 reference

12 December 2020

PET: the merging of biology and imaging into molecular imaging.

1 reference

12 December 2020

The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain

1 reference

12 December 2020

Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34.

1 reference

12 December 2020

Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease

1 reference

12 December 2020

Amyloid binding ligands as Alzheimer's disease therapies

1 reference

12 December 2020

Hydrogen magnetic resonance spectroscopy in Alzheimer's disease

1 reference

12 December 2020

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

12 December 2020

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

1 reference

12 December 2020

EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: I--Factors associated with carer burden

1 reference

12 December 2020

Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease.

1 reference

12 December 2020

Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies

1 reference

12 December 2020

Development of a monoclonal antibody specific for beta/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy

1 reference

12 December 2020

Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease

1 reference

12 December 2020

Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease.

1 reference

12 December 2020

From healthy aging to early Alzheimer's disease: in vivo detection of entorhinal cortex atrophy

1 reference

12 December 2020

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

1 reference

12 December 2020

Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia

1 reference

12 December 2020

Added Clinical Benefit of Incorporating 2-Deoxy-2-[F]Fluoro-D-Glucose with Positron Emission Tomography into the Clinical Evaluation of Patients with Cognitive Impairment

1 reference

12 December 2020

Staging of Alzheimer-related cortical destruction

1 reference

12 December 2020

Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice.

1 reference

12 December 2020

Biphenyls labeled with technetium 99m for imaging beta-amyloid plaques in the brain

1 reference

12 December 2020

The epidemic of Alzheimer's disease. How can we manage the costs?

1 reference

12 December 2020

The molecular pathology of Alzheimer's disease

1 reference

12 December 2020

Current progress in beta-amyloid immunotherapy

1 reference

12 December 2020

Collection and normal levels of the amyloid precursor protein in plasma

1 reference

12 December 2020

Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study

1 reference

12 December 2020

Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: normal development, aging, dementia, and stroke

1 reference

12 December 2020

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

1 reference

12 December 2020

M<sub>1</sub> Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future Therapy

1 reference

12 December 2020

Tau neurofibrillary pathology and microtubule stability

1 reference

12 December 2020

Brain SPECT in neurology and psychiatry.

1 reference

12 December 2020

Development of amyloid imaging PET probes for an early diagnosis of Alzheimer's disease.

1 reference

12 December 2020

Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease.

1 reference

12 December 2020

[(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results.

1 reference

12 December 2020

Amyloid, the presenilins and Alzheimer's disease

1 reference

12 December 2020

Mild cognitive impairment represents early-stage Alzheimer disease

1 reference

12 December 2020

Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease

1 reference

12 December 2020

Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease.

1 reference

12 December 2020

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome

1 reference

12 December 2020

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report

1 reference

12 December 2020

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

1 reference

12 December 2020

Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease.

1 reference

12 December 2020

PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis

1 reference

12 December 2020

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

1 reference

12 December 2020

Impact of amyloid imaging on drug development in Alzheimer's disease

1 reference

12 December 2020

beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

1 reference

12 December 2020

Subtype of mild cognitive impairment and progression to dementia and death

1 reference

12 December 2020

Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway

1 reference

12 December 2020

Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography.

1 reference

12 December 2020

Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain

1 reference

12 December 2020

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

1 reference

12 December 2020

1 reference

12 December 2020

Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees

1 reference

12 December 2020

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

1 reference

12 December 2020

Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.

1 reference

12 December 2020

Part I. Epidemiology and public health impact of Alzheimer's disease

1 reference

12 December 2020

Distribution volume ratios without blood sampling from graphical analysis of PET data

1 reference

12 December 2020

Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings

1 reference

12 December 2020

In vivo brain imaging of tangle burden in humans

1 reference

12 December 2020

Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy

1 reference

12 December 2020

Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections.

1 reference

12 December 2020

On the seeding and oligomerization of pGlu-amyloid peptides (in vitro)

1 reference

12 December 2020

Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain

1 reference

12 December 2020

10.1007/S12035-008-8019-Y

Identifiers

DOI

1 reference

19 August 2017

1 reference